Previous 10 | Next 10 |
home / stock / mpsyf / mpsyf news
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Recent Strategy outperformance has been broad-based, led ...
M&A activity increases with eight new deals announced. Welbilt terminates its deal with The Middleby Corporation and agrees to be acquired by Ali Group. Monmouth Real Estate Investment Corporation receives an unsolicited acquisition proposal from a large private investment fir...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Recent Strategy outperformance has been broad-based, led ...
Regional bank consolidation continues with three new bank deals announced last week. Extended Stay America catches a higher bid. Chamath Palihapitiya files for four new biotech-focused SPACs. For further details see: Merger Arbitrage Mondays: Extended Stay America Receiv...
Constellation Pharmaceuticals (CNST) has climbed ~61.3% in the pre-market after announcing an agreement with MorphoSys AG (MPSYF) whereby MorphoSys will acquire Constellation for $34.00 per share in cash for a total equity value of ~$1.7B.Per the terms of the agreement, which i...
MorphoSys AG (MOR) Q1 2021 Earnings Conference Call May 06, 2021 08:00 AM ET Company Participants Julia Neugebauer - Senior Director of Investor Relations Jean-Paul Kress - Chief Executive Officer Roland Wandeler - Chief Operating Officer Sung Lee - Chief Financial Officer Malte Peters - Chie...
The following slide deck was published by MorphoSys AG in conjunction with their 2021 Q1 earnings call. For further details see: MorphoSys AG 2021 Q1 - Results - Earnings Call Presentation
The following slide deck was published by MorphoSys AG in conjunction with their 2020 Q4 earnings call. For further details see: MorphoSys AG 2020 Q4 - Results - Earnings Call Presentation
MorphoSys AG (MOR) Q4 2020 Earnings Conference Call March 16, 2021 9:00 a.m. ET Company Participants Julia Neugebauer - Director, IR Jean-Paul Kress - CEO Roland Wandeler - COO Malte Peters - Chief R&D Officer Sung Lee - CFO Conference Call Participants Geoffrey Porges - SVB Leerink James...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. 2020 was a year of monumental progress in renewable energ...
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Ord Company Name:
MPSYF Stock Symbol:
OTCMKTS Market:
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...